First Trust NYSE Arca Biotech Index Fd

Neurocrine Biosciences advances Phase II clinical trial for NBI-1065890

Neurocrine Biosciences Director Richard F. Pops Sells 15,000 Shares for $2.36 Million

Neurocrine Biosciences Releases Real-World Data Confirming INGREZZA's Improvement in Tardive Dyskinesia

Oppenheimer Raises Biogen Price Target to $300, Maintains Outperform Rating

Veracyte Receives Medicare Coverage for Bladder Cancer Test, Orders Open June 1

TD Cowen Reaffirms Buy Rating on Biogen with $215 Price Target

Biogen Finalizes Acquisition Agreements with Apellis: Establishes SYFOVRE Milestone CVR and Secures $2 Billion Loan

Biogen Advances Alzheimer's Drug to Late Trials Despite Mid-Stage Failure, Shares Jump 6%

Biogen Announces Positive Phase 2 Results for Ionis Partner Drug Diranersen in Alzheimer's Disease

Biogen announces Alzheimer's drug fails to meet primary endpoint in mid-stage trial

Arrowhead Advances RNAi Pipeline, REDEMPLO Launches with Over 400 Prescriptions in First Quarter

Illumina CEO joins China delegation, stock price rises

Alkermes Announces Positive Top-Line Results for Lumryz® in Adult Idiopathic Hypersomnia Phase III Study

Axsome Therapeutics Receives FDA Approval for AUVELITY

Mizuho Raises Axsome Therapeutics Price Target to $310

Leqembi® Iqlik™ PDUFA date updated to August 24th

FDA Prioritizes Review of LEQEMBI® IQLIK™ Subcutaneous Injection for Early Alzheimer's Disease

Arrowhead Pharmaceuticals Announces Q2 2026 Earnings Report with Increased Net Loss

Arrowhead Pharmaceuticals Q2 Revenue Falls Short of Estimates

ArrowHead Pharma released FY2026 Semi-Annual earnings on May 7 During-Market (EST), actual revenue USD 337.77 M, actual EPS USD -0.73

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

Pinned News

置顶新闻

GraniteShares Files High-Octane 2X ETFs Tied To Nuclear, AI, Biotech Momentum Stocks

MGRX

ARKG

SBIO

LABU

Mangoceuticals, Inc. reported Q1 2026 revenue of $67.9K, down 37.9% from $109.3K in Q1 2025, with a net loss of $3.7M and a diluted EPS of $(0.22). The decline is attributed to a focus on in-house website development and TRT testing. The company is shifting to third-party fulfillment and plans to commercialize new products, including Dermytol in Q3 2026, while implementing cost controls.

TradingView

Mangoceuticals

VG Health

Proshares Ultra Nasdaq Biotech

iShares US Healthcare Providers

Invesco Biotechnology & Genome ETF

SPDR S&P Health

iShares Biotechnology ETF

iShares Global Healthcare

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

SPDR S&P Biotech

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

iShares US Pharma

Health Care Select Sector SPDR

MANGOCEUTICALS, INC. 1Q 2026: Revenue $67.9K, EPS $(0.22) — 10-Q Summary

Danaher Corp. (DHR) shares rose 1.94% to $167.04 on a challenging trading day for the market, outperforming competitors like Thermo Fisher, Abbott, and Medtronic. The stock is still 31.20% below its 52-week high of $242.80. Trading volume reached 5.7 million, surpassing the 50-day average of 4.6 million.

MarketWatch Automated

Danaher

iShares US Medical Devices

SPDR S&P Health Equip

S&P 500

Dow Jones Industrial Average

Thermo Fisher Scentific

Abbott Laboratories

Medtronic

Danaher Corp. Stock Outperforms Competitors On Strong Trading Day

Pfizer Inc. (PFE) shares rose 1.30% to $25.66 on a challenging trading day for the market, outperforming competitors like Johnson & Johnson and Eli Lilly. Despite the gain, Pfizer remains 10.73% below its 52-week high of $28.75. The trading volume reached 40.9 million, surpassing its 50-day average of 37.8 million.

- Shares of Pfizer Inc. (PFE) increased by 1.30% to $25.66 amid a generally negative trading day for the stock market.  
- The stock remains 10.73% below its 52-week high of $28.75, reached on April 2nd, while competitors like Johnson & Johnson and Eli Lilly saw gains.  
- Trading volume for Pfizer was 40.9 million, surpassing its 50-day average of 37.8 million.

Pfizer

Invesco Nasdaq Biotechnology ETF

Johnson & Johnson

Eli Lilly

Pfizer Inc. Stock Outperforms Competitors On Strong Trading Day

IMRX

Chardan Capital analyst Geulah Livshits has reiterated a Buy rating on Immuneering (IMRX) with a price target of $20.00. Livshits, who focuses on the Healthcare sector, has an average return of 7.8% and a 35.98% success rate on recommended stocks. Mizuho Securities also maintained a Buy rating on the stock, setting a price target of $12.00.

Tip Ranks

Immuneering

Palvella Therapeutics

Iovance Biotherapeautics

Tenaya Therapeutics

Mizuho Financial

Mizuho Financial Group, Inc.

Immuneering (IMRX) Gets a Buy from Chardan Capital

Thermo Fisher Scientific Inc. (TMO) shares rose 1.31% to $447.81 on Tuesday, outperforming a declining market where the S&P 500 fell 0.67% and the Dow Jones dropped 0.65%. This marks the second consecutive day of gains for the stock, which remains 30.46% below its 52-week high of $643.99 reached on January 22nd. Trading volume was 3.4 million, surpassing the 50-day average of 2.2 million.

Factset Research

Thermo Fisher Scientific Inc. Stock Rises Tuesday, Outperforms Market

AMGN

Amgen Inc. (AMGN) shares rose 1.96% to $330.75 on a weak trading day for the market, breaking a three-day losing streak. Despite this gain, the stock remains 15.47% below its 52-week high of $391.29. Competitors like Johnson & Johnson, Pfizer, and AbbVie also saw gains, with trading volume surpassing its 50-day average.

Amgen

Abbvie

Amgen Inc. Stock Outperforms Competitors On Strong Trading Day

Regencell Bioscience has announced a registered direct offering of 985,222 ordinary shares priced at $20.30 each, aiming for gross proceeds of approximately $20 million. The offering is led by a $19 million investment from a new institutional investor, with closing expected around May 20, 2026, subject to customary conditions. Univest Securities is the sole placement agent.

PUBT

Regencell Bioscience

Univest Financial

Regencell Bioscience prices 985,222-share registered direct offering at $20.30 each

ABBV

AbbVie Inc. (ABBV) shares rose 2.08% to $213.76 on a challenging trading day for the market, outperforming competitors like Johnson & Johnson and Pfizer. The stock ended 12.68% below its 52-week high of $244.81. Trading volume reached 7.1 million, surpassing the 50-day average of 6.9 million.

AbbVie Inc. Stock Outperforms Competitors On Strong Trading Day

ETON

Eton Pharmaceuticals has secured exclusive U.S. commercialization rights to the leishmaniasis drug IMPAVIDO (miltefosine) through a supply and distribution agreement with a Knight Therapeutics affiliate. The rights will take effect on September 26, 2026, contributing to Eton's rare disease portfolio and marking another product launch planned for that year. IMPAVIDO is the only FDA-approved oral treatment for certain forms of leishmaniasis.

Eton Pharmaceuticals

Eton Pharmaceuticals secures US commercialization rights to leishmaniasis drug Impavido

OCUL

Ocular Therapeutix reported Q1 2026 results with revenue of $10.79 million and a net loss of $88.61 million, indicating a significant investment burden despite stable revenue. The company's future hinges on the success of its AXPAXLI trials, with a projected revenue of $335.8 million by 2029. Analysts express concerns over rising losses and dependence on AXPAXLI, with fair value estimates ranging from $18.00 to $26.00 per share.

Simplywall

Ocular Therap

Can Ocular Therapeutix's (OCUL) Rising Losses on Flat Revenue Still Support Its R&D Ambitions?

BBIO

BridgeBio Pharma director Randal W. Scott sold USD 655,873 in common shares, reducing his stake to 11,589 shares. He exercised options for 10,000 shares at USD 16.75 and sold them at prices between USD 66.69 and USD 69.12. Scott also holds 4,000 shares indirectly through Thinking Bench Capital LLC.

Bridgebio Pharma

BridgeBio director Randal W. Scott sells USD 655,873 in common shares

Novo Nordisk AS

Defiance Daily Target 2X Long LLY ETF

Direxion Daily LLY Bear 1X Shares

Novo Nordisk's U.S. stock pre-market fell 11%, while Eli Lilly rose over 4% in pre-market trading. Novo Nordisk's CagriSema performed worse than Eli Lilly's Zepbound in trials

Wallstreetcn

First Trust NYSE Arca Biotech Index Fd(FBT.US)

MANGOCEUTICALS, INC. 1Q 2026: Revenue $67.9K, EPS $(0.22) — 10-Q Summary

Danaher Corp. Stock Outperforms Competitors On Strong Trading Day

Pfizer Inc. Stock Outperforms Competitors On Strong Trading Day

Immuneering (IMRX) Gets a Buy from Chardan Capital

Thermo Fisher Scientific Inc. Stock Rises Tuesday, Outperforms Market